-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Talazoparib in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Talazoparib in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Talazoparib in Refractory Acute Myeloid Leukemia Drug Details: Talazoparib (Talzenna,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gotistobart in Head And Neck Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gotistobart in Head And Neck Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gotistobart in Head And Neck Carcinoma Drug Details: ONC-392 is...
-
Product Insights
NewAdenoid Cystic Carcinoma (ACC) – Drugs In Development, 2024
Empower your strategies with our Adenoid Cystic Carcinoma (ACC) – Drugs In Development, 2024 report and make more profitable business decisions. Adenoid cystic carcinoma (ACC) is a rare and aggressive type of cancer that originates from glandular tissues. It can occur in various parts of the body, but it is most found in the salivary glands of the head and neck region. ACC is characterized by a MYB oncogene activation and a tendency to invade nerves and metastasize to distant organs....
-
Product Insights
NewAnal Cancer – Drugs In Development, 2024
Empower your strategies with our Anal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, and narrowing of stool. Predisposing factors include HPV infections, smoking, and lowered immunity. The Anal Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Anal...
-
Product Insights
NewAdenocarcinoma – Drugs In Development, 2024
Empower your strategies with our Adenocarcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Adenocarcinoma is a type of cancer that starts in mucus-producing (glandular) cells. Many organs have these types of cells and adenocarcinoma can develop in any of these organs. The symptoms of adenocarcinoma will depend on which organ is affected by cancer. The patients may not experience any symptoms until the cancer is more advanced. The Adenocarcinoma drugs in development market research report provide...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Arsenic Trioxide in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Arsenic Trioxide in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Arsenic Trioxide in Mantle Cell Lymphoma Drug Details: Arsenic trioxide...